Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

NCT00130871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Heart Disease

Interventions

DRUG: levosimendan

Sponsor

Orion Corporation, Orion Pharma